Global Guillain-Barre Syndrome Market by Type (Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy), Treatment (Hydrotherapy, Medication, Physical Therapy), End-User - Forecast 2024-2030- Product Image

Sale

Global Guillain-Barre Syndrome Market by Type (Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy), Treatment (Hydrotherapy, Medication, Physical Therapy), End-User - Forecast 2024-2030

Report
180 Pages
March 2024
Region: Global
360iResearch™
ID: 5715770

UP TO €846EUR$875USD£725GBP OFF until Dec 31^st 2024

The Guillain-Barre Syndrome Market size was estimated at USD 634.43 million in 2023, USD 665.39 million in 2024, and is expected to grow at a CAGR of 2.10% to reach USD 734.24 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Guillain-Barre Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Guillain-Barre Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Guillain-Barre Syndrome Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics Plc, Annexon Inc., Cellenkos Inc., CSL Limited, CuraVac Europe S.A., Electrical Geodesics Inc., Grifols S.A., Hansa Biopharma, Kedrion Biopharma Inc., Octapharma AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Guillain-Barre Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Acute Inflammatory Demyelinating Polyneuropathy
- Acute Motor & Sensory Axonal Neuropathy
- Acute Motor Axonal Neuropathy
- Miller Fisher Syndrome
Treatment
- Hydrotherapy
- Medication
- Physical Therapy
- Plasmapheresis
End-User
- Diagnostic Centers
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Guillain-Barre Syndrome Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Guillain-Barre Syndrome Market?
What are the technology trends and regulatory frameworks in the Guillain-Barre Syndrome Market?
What is the market share of the leading vendors in the Guillain-Barre Syndrome Market?
Which modes and strategic moves are suitable for entering the Guillain-Barre Syndrome Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Guillain-Barre Syndrome Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of Guillain-Barre syndrome worldwide
5.1.1.2. Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
5.1.1.3. Rising consumer healthcare awareness and expenditures
5.1.2. Restraints
5.1.2.1. High costs of treatment and drugs
5.1.3. Opportunities
5.1.3.1. Advances in management of Guillain-Barre syndrome
5.1.3.2. Favorable governmental reimbursement policies for rare diseases
5.1.4. Challenges
5.1.4.1. Less awareness towards disease diagnosis and treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Guillain-Barre Syndrome Market, by Type

6.1. Introduction
6.2. Acute Inflammatory Demyelinating Polyneuropathy
6.3. Acute Motor & Sensory Axonal Neuropathy
6.4. Acute Motor Axonal Neuropathy
6.5. Miller Fisher Syndrome

7. Guillain-Barre Syndrome Market, by Treatment

7.1. Introduction
7.2. Hydrotherapy
7.3. Medication
7.4. Physical Therapy
7.5. Plasmapheresis

8. Guillain-Barre Syndrome Market, by End-User

8.1. Introduction
8.2. Diagnostic Centers
8.3. Hospitals

9. Americas Guillain-Barre Syndrome Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Guillain-Barre Syndrome Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Guillain-Barre Syndrome Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Akari Therapeutics Plc
13.1.2. Annexon Inc.
13.1.3. Cellenkos Inc.
13.1.4. CSL Limited
13.1.5. CuraVac Europe S.A.
13.1.6. Electrical Geodesics Inc.
13.1.7. Grifols S.A.
13.1.8. Hansa Biopharma
13.1.9. Kedrion Biopharma Inc.
13.1.10. Octapharma AG
13.1.11. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. GUILLAIN-BARRE SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GUILLAIN-BARRE SYNDROME MARKET DYNAMICS
FIGURE 7. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR & SENSORY AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MILLER FISHER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 16. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 129. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 138. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 146. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. GUILLAIN-BARRE SYNDROME MARKET LICENSE & PRICING

Companies Mentioned

Akari Therapeutics Plc
Annexon Inc.
Cellenkos Inc.
CSL Limited
CuraVac Europe S.A.
Electrical Geodesics Inc.
Grifols S.A.
Hansa Biopharma
Kedrion Biopharma Inc.
Octapharma AG
Takeda Pharmaceutical Company Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	180
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 665.39 Million
Forecasted Market Value ( USD ) by 2030	$ 734.24 Million
Compound Annual Growth Rate	2.1%
Regions Covered	Global
No. of Companies Mentioned	11

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,796GBP €3625EUR$3,749USD£3,107GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,542GBP €4593EUR$4,749USD£3,936GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,288GBP €5560EUR$5,749USD£4,765GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£5,034GBP €6527EUR$6,749USD£5,594GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,526GBP €8461EUR$8,749USD£7,251GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

Guillain-Barre Syndrome Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Guillain-Barre Syndrome Therapeutics: Global Strategic Business Report

Europe Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Guillain-Barre Syndrome - Pipeline Insight, 2024

About the Guillain Barre Syndrome Drug Market